A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients.

Evaluation of clinical outcomes in patients undergoing dual vessel percutaneous coronary intervention using sirolimus-eluting coronary stent system in India. J Clin Diagn Res (2015) 0.76

Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. BMJ Open (2016) 0.75

Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. Scientifica (Cairo) (2016) 0.75

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84

Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77

Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37

Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68

Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84

Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82

Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol (2005) 3.38

Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med (2003) 2.79

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34

Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J (2008) 2.01

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80

Coronary artery stents. JAMA (2000) 1.70

Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 1.62

Vessel size and long-term outcome after coronary stent placement. Circulation (1998) 1.61

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56

Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). J Invasive Cardiol (2007) 1.43

Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol (2003) 1.29

Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol (2009) 1.26

3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv (2009) 1.26

Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol (2001) 1.17

Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J (2007) 1.10

Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J (2004) 0.99

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv (2007) 0.92

Molecular biology and post-angioplasty restenosis. Atherosclerosis (1996) 0.91

Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol (2006) 0.90

First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention (2005) 0.88

Current status of biodegradable stents. Cardiol Clin (1994) 0.86

Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials. Eur Heart J (2004) 0.83

Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA (2011) 3.28

Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. Catheter Cardiovasc Interv (2013) 1.46

Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry. Indian Heart J (2009) 1.42

Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am Heart J (2008) 0.83

In vivo assessment of stent recoil of biodegradable polymer-coated cobalt-chromium sirolimus-eluting coronary stent system. Indian Heart J (2012) 0.81

A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. Am Heart J (2011) 0.78

One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. Indian Heart J (2013) 0.78

The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study. Indian Heart J (2013) 0.78

Real-time three-dimensional transthoracic echocardiography. Indian Heart J (2005) 0.77

A case of type I variant Kounis syndrome with Samter-Beer triad. World J Cardiol (2013) 0.75

Percutaneous balloon pericardiotomy in a patient with end stage renal disease with recurrent pericardial effusion & pericardial tamponade. Indian Heart J (2010) 0.75

Acute myocardial infarction. Indian Heart J (2012) 0.75

First-in-Human Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The MyVal-1 Study. EuroIntervention (2019) 0.75

Use of PercuSurge in primary angioplasty. Indian Heart J (2005) 0.75

Primary angioplasty: issues in present day practice. Indian Heart J (2012) 0.75